Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURE-02: Perioperative Trodelvy + Keytruda in MIBC
NCT05535218Phase 2Active, not recruiting
- Start
- Sep 2023
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan, pembrolizumab in muscle-invasive bladder cancer (MIBC). Started Sep 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05535218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535218.